KRAS / RAS targeting: from platform to Phase 3
Chinese groups are not short of G12C molecules (elisrasib’s floor numbers are strong).
🆕 Next-gen KRAS G12C inhibitor elisrasib induced:
➡️ Tumor shrinkage in 60% (resistant pts)
➡️ Molecular responses in most pts with KRAS G12C+ NSCLC
High target engagement translating clinically.
🗣️ Presented by Byoung Chul Cho, MD, PhD at #AACR26
🔗 https://t.co/M3nu8d7FFC https://t.co/4CE8iv0alW
Heat 3 · 0 likes · 1 reply · 2 reposts
Kanwal Pratap Raghav, Jun Zhang, Myung-Ah Lee, Jingdong Zhang, John Park, Yanqiao Zhang, Susana Rosello Keranen, Byoung Chul Cho, Herbert Ho Fung Loong, Cheng Chen, Huan Li, Shaonan Wang, Yandong Shen, Zifei Fan, Qian Chen, Hui Wang, Jing Zhang, George Zhi Jian Chen, Jayesh Desai, Antoine Hollebecque
Read the abstract →Source: x.com · x.com